• PKCe, regulating RhoA activity, is a critical mediator of proplatelet formation.
Introduction
Defective platelet numbers can compromise proper wound healing and cause bleeding, whereas excessive platelet production or activation can lead to thrombosis. As a result, platelet homeostasis is a tightly regulated process. The process of generating thousands of platelets from a single megakaryocyte is characterized by several morphologically distinct stages that involve extensive cytoskeletal remodeling. In particular, megakaryoctyes, following polyploidization and prior to platelet release, form elongated cellular processes called proplatelets (proPLT). 1 Perturbations in proPLT formation lead to alterations in platelet morphology and thrombocytopenia, 2, 3 emphasizing the importance of this step. The marginal microtubule band, actin-based cytoskeleton, and spectrin-based membrane skeleton are all prominent components of the cytoskeletal remodeling that occurs during platelet formation. 4 Specifically, dynamic tubulin polymerization is required for the proper platelet morphology, assembly of the marginal microtubule coil, proPLT extensions and microtubule band formation. [4] [5] [6] [7] [8] Various mutations in genes that regulate actin polymerization and turnover cause thrombocytopenia due to altered formation and morphology of proPLT extensions, increased platelet size, and defective platelet release. 9, 10 The spectrin cytoskeleton membrane influences platelet formation by supporting the megakaryocyte membrane invagination that is critical to the production of proPLT extensions. 11 In addition to these cytoskeletal pillars, the Rho/Rho-associated, coiled-coil containing protein kinase (ROCK) pathway regulates platelet production. Overexpression of a dominant-negative RhoA boosts proPLT formation, whereas constitutive RhoA activation abrogates this process. 12 Moreover, blocking RhoA activity is necessary for microtubule-driven formation of proPLT cytoplasmic extensions. 13 RhoA-deficient mice display macrothrombocytopenia, suggesting that RhoA activity must be temporally regulated for successful PLT production. 14 There are implications that RhoA signaling influence platelet formation by regulating cytoskeleton components. For example, it has been demonstrated that the correlation between PLT size and changes in tubulin polymerization involves a RhoA/ Rho-dependent regulation of cytoskeletal microtubule ring remodeling. 2, 15 Furthermore, RhoA contributes to actin function during actomyosin contractility and stress fiber formation. 16 Additionally, the Rho/ROCK pathway is related to the late failure of cytokinesis responsible for the endomitotic process in megakaryocytes. 17 We recently showed that expression of protein kinase Cepsilon (PKCe), a member of the protein kinase C family of serine/ threonine kinases, changes throughout the course of thrombopoietin (TPO)-induced megakaryocyte (MK) differentiation from human CD34 pos cells. 18, 19 PKCe has been implicated in both the regulation of cytoskeleton remodeling and the RhoA pathway. 20 Specifically, PKCe, unlike other PKC family members, contains an F-actinbinding region that promotes the formation of F-actin filaments by preventing depolymerization and increasing the rate of actin filament elongation. 21 During mitotic cytokinesis of several cell types (ie, COS-7, HeLa, MEF, HEK 293), PKCe assembles with 14-3-3zeta, and together they transiently accumulate at the actomyosin ring with RhoA and is required to dissociate both itself and RhoA from the midbody. 22 In neurons, PKCe promotes neurite outgrowth, which can be blocked by forced activation of the ROCK/RhoA pathway, indicating that PKCepilson may attenuate RhoA/ROCK pathway activity in the process. 23 On these bases we hypothesized that PKCe regulates proPLT formation by modulating RhoA activity. Indeed, our data show that PKCe shut down results in RhoA expression levels that are incompatible with normal PLT generation.
Methods

Cell isolation and cell cultures
Mouse fetal liver cells (FLC) were isolated from embryos at day 13.5. Singlecell suspensions were prepared as previously described 24 and cultured for 4 days in Dulbecco's modified Eagle medium (Invitrogen, Carlsbad, CA), supplemented with 10% fetal calf serum, 2 mmol/L l-glutamine, 50 U/mL penicillin, and 50 mg/mL streptomycin at 37°C and 5% CO 2 in the presence of 0.1 mg/mL purified recombinant mouse TPO. 25 All experiments were complied with institutional guidelines approved by the Children's Hospital Animal Care and Use Committee and the Institutional Animal Care and Use Committee.
Isolation of MK and proPLT
FLC cultures were layered on a single-step gradient (1.5% to 3.0% bovine serum albumin [BSA] ) at different times of differentiation (days 2, 3, 4, 5), and MKs were allowed to sediment for 30 minutes. For proPLT production analysis, the isolated MKs were resuspended in fresh media and cultured for an additional 24 hours, during which proPLT production was readily observed. For some experiments, MK cultures were layered on a second single-step gradient (1.5% to 3.0% BSA) on day 5. MKs were allowed to sediment for 30 minutes, during which intermediate stages in PLT production were resolved within different fractions of the gradient. 26 Round MKs (rMK) sedimented on the bottom, and proPLT-forming MKs (ppfMK) localized to the BSA fraction, whereas released proPLTs and individual PLTs remained in the top fraction.
Immunofluorescence microscopy
Mouse MKs, culture intermediates, and PLTs were purified and probed as previously described. 27 In brief, samples were fixed in 4% formaldehyde, centrifuged onto 1 mg/mL poly-l-lysine-coated coverslips, permeabilized, and blocked 8 before antibody labeling. Samples were incubated with mouse monoclonal antibodies against a and b tubulin (Sigma-Aldrich, St. Louis, MO) and a rabbit monoclonal antibody against PKCe (Novus Biologicals, Littleton, CO). They were treated with secondary goat anti-mouse and goat anti-rabbit antibodies, conjugated to an Alexa Fluor 568 and to an Alexa Fluor 488 (Invitrogen), respectively; 4,6 diamidino-2-phenylindole (DAPI) (SigmaAldrich) was used to label the MK nucleus. Samples were examined with a microscope (Axiovert 200, Carl Zeiss, Inc.,Oberkochen, Germany) equipped with a 633 numerical aperture 1.4 oil immersion objective. Images were obtained using a charge-coupled device (CCD) camera (Hamamatsu Photonics, Hamamatsu, Japan) and analyzed using the MetaMorph image analysis software (MDS Analytical Technologies, Sunnyvale, CA).
Further images were acquired with a confocal microscope Olympus FluoView™ FV10i (Center Valley, PA), with a 603 water corrected objective. Series of x-y images were collected along the z-axis at 0.1-or 0.5-mm intervals. Three individual images were averaged to generate a representative image for each sample plane. At least 7 averaged images were collected at 0.5-mm steps along the z-axis of each sample for both fluorescence channels. Image analysis was generated using ImageJ software (National Institutes of Health, Bethesda, MD).
Cell perimeter and diameter were analyzed using the MetaMorph software thresholding, integrated morphometry analysis, and software calipers tools and by ImageJ software. Experiments represent 1 standard deviation about the mean for at least 3 independent cultures.
shRNA cell infection
For short hairpin RNA (shRNA)-based gene silencing, pLKO.1 lentiviral vector encoding shRNA against mouse PKCe (NM_011104; shRNA59 and shRNA60) were obtained from Open-Biosystem (Thermo Scientific, Waltham, MA). As control (shRNACT), we used the MISSION pLKO.1-puro NonTarget shRNA Control Plasmid, containing a shRNA insert that does not target any known genes from any species (Sigma-Aldrich). The shRNA expressing viruses were produced in 293TL cells according to standard protocols. Mouse FLCs were infected at day 0 of culture and then cultured with TPO in the presence of puromycin, to select infected, puromycin-resistant cells.
PKCe was downmodulated in primary MK progenitors infecting FLCs with specific shRNA at day 0 of culture. Infected cells were cultured with TPO in the presence of puromycin, for cell selection. At day 4 of culture, infected rMKs were isolated by BSA gradient and cultured for an additional 24 hours in the presence of TPO and puromycin. At day 5 of culture, cells were analyzed for proPLT formation by light microscopy and then fixed for immunofluorescence staining.
Aliquots from each culture were collected for western blot analysis.
Inhibition of RhoA
At day 4 of culture, infected rMKs were isolated by BSA gradient and cultured for an additional 24 hours in the presence of TPO and puromycin, with or without C3 transferase RhoA inhibitor (Cytoskeleton, Inc., Denver, CO). At day 5 of culture, cells were analyzed for proPLT formation by light microscopy and then fixed for immunofluorescence staining, and a fixed volume of culture supernatants were collected for PLT count by flow cytometry.
PLT count by flow cytometry
PLT production in culture was quantified as previously described. 19, 28 Briefly, fixed volumes of the culture supernatants were collected, incubated with anti-CD41-RPE and Calcein AM (Sigma-Aldrich) (to exclude fragments), and added to a fixed volume of calibration beads (DAKO, Glostrup, Denmark) (size of beads of known concentration). CD41 pos /Calcein AM pos PLTs were quantified by flow cytometry and normalized to bead counts to determine absolute PLT counts.
Western blot
Cultured cells were counted, and 1.5 3 10 6 cells were collected on days 0, 2, 3, 4, and 5, washed in phosphate-buffered saline, and centrifuged at 200 g for 10 minutes. Pellets were resuspended in a cell lysis buffer (50 mM Tris-HCl, pH 7.4; 1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM phenylmethylsulfonyl fluoride; 1 mM Na 3 VO 4 ; 1 mM NaF), supplemented with fresh protease inhibitors, and protein concentration was determined using a Pierce BCA protein assay kit (Thermo Scientific). Thirty micrograms of proteins from each sample were run on 4% to 20% sodium dodecyl sulfate-acrylamide gels (Bio-Rad, Hercules, CA), blotted onto nitrocellulose membranes, blocked, and incubated with specific primary antibodies diluted as described in manufacturers' protocols. Specifically, rabbit polyclonal anti-PKCe antibody (catalog number: 06991; Merck Millipore, Darmstadt, Germany) was used at the concentration of 1 mg/mL. Mouse monoclonal anti-PKCd antibody (BD Pharmingen, San Jose, CA) was diluted 1:500, rabbit polyclonal anti-PKCu antibody (Cell Signaling, Danvers, MA) was diluted 1:1000, rabbit polyclonal anti-PKCa antibody (Cell Signaling) was diluted 1:1000, and rabbit polyclonal anti-14-3-3zeta antibody (catalog number: AB9746; Merk Millipore) was diluted 1:500. A mouse monoclonal anto-RhoA antibody (Cytoskeleton, Inc.) was diluted 1:500, and mouse monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (catalog number: MAB374; Merk Millipore), 1:5000 dilution) used as a protein-loading control.
Membranes were washed and incubated for 1.5 hours at room temperature with 1:5000 peroxidase-conjugated anti-rabbit or with 1:2000 peroxidase-conjugated anti-mouse IgG (Pierce) at room temperature and resolved by ECL Supersignal West Pico Chemiluminescent Substrate detection system (Pierce). Protein densitometric analyses from western blot assays were performed by using the Image J software system, normalized for GAPDH expression levels.
Statistical analyses were performed by using analysis of variance (ANOVA) and Tukey tests.
Results
PKC« levels are modulated during MK differentiation
In agreement with our previous studies in human megakaryocyte coltures, 18 PKCe protein expression increases during the early phases of MK differentiation ( Figure 1A ). However, unlike human megakaryopoiesis, mouse PKCe remains highly expressed throughout the entire maturation process, including PLT release (relative densitometric measurements of the samples tested are shown in Figure 1B ).
Both morphological and confocal immunofluorescence analyses of differentiating MKs show that progressively enlarged, multinucleated cells stably express PKCe and a/b-Tubulin, the main cytoskeletal protein comprising the marginal tubular coil, 5 and that PKCe colocalizes with a/b-Tubulin dimers at the marginal tubular coil of proPLTs ( Figure 1C) . Indeed in the cytoplasm, PKCe staining appears diffuse, with no evident overlapping with a/b-Tubulin. On the contrary, a strong overlap of PKCe with a/b-Tubulin is present along all the proPLT extensions and the marginal tubular coils, as shown in the composite panel of Figure 1C .
PKC« expression is necessary for proPLT formation
We then sought to determine whether PKCe expression was necessary for proplatelet production. Therefore we used recombinant lentiviral vectors to introduce and stably express shRNA molecules that specifically target PKCe into FLC at day 0 of culture. Analysis of megakaryocyte cultures at day 5 postinfection revealed that abrogation of PKCe was specific, because it did not modify either the expression of the other novel PKC isoforms or that of PKC a (Figure 2A-B) . Morphological analyses of isolated megakaryocytes revealed that inhibition of PKCe expression resulted in the production of more aberrant proPLTs in comparison with control cultures ( Figure 2C ). The shRNA60 was more effective than shRNA59 in proPLT inhibition. However, although few residual branched protrusions could still be observed, proPLTs generated by both shRNA-infected cells were characterized by few abortive branches with some residual PKCe staining and virtual absence of the discoid structures. On the contrary, shRNACT proPLTs, characterized by the presence of discoid structures, expressed PKCe both in the cytoplasm and in the marginal tubular coil, where it appears particularly bright ( Figure 2D ). Moreover, we observed a greater than 70% reduction in platelet numbers in cultures in which we introduced PKCe shRNAs, and the remaining released PLTs were bigger than normal with a blurred tubulin-formed marginal tubular coil ( Figure 2D insert), consistent with a defective cytoskeletal organization. Similar results were observed also by the inhibition of PKCe expression using specific small interfering RNA (siRNA) (supplemental data found on the Blood Website).
PKC« modulates RhoA in MK progenitors
In certain cell types, PKCe cooperates with the 14-3-3zeta isoform to inhibit RhoA activity and drive cell division. 22 RhoA levels are also downmodulated in the later phases of thrombopoiesis to allow MK polyploidization 29 and cytoskeletal rearrangement. 30 Western blot analyses of TPO-treated FLCs over the course of MK differentiation revealed that active and cleaved RhoA levels diminish at day 5 post-TPO stimulation, when rMK start producing proPLTs. On the contrary, the expression of both PKCe and 14-3-3zeta escalates Each image represents a projection from a z-stack of 7 images collected at 0.5-mm increments. Images were obtained at 22°C and analyzed by ImageJ software. PKCe was detected with a rabbit polyclonal antibody and a secondary goat anti-rabbit antibody, conjugated to an Alexa Fluor 488; a and b tubulin were detected with mouse monoclonal antibodies and a secondary goat anti-mouse antibody, conjugated to an Alexa Fluor 568; MK nucleus was detected with DAPI. BLOOD, 15 AUGUST 2013 x VOLUME 122, NUMBER 7 PKCe IN MOUSE MEGAKARYOCYTOPOIESIS 1307
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Next, we examined whether modulating PKCe expression impacted RhoA activity during proPLT formation. Though abrogation of PKCe expression in primary MK precursors did not affect 14-3-3zeta levels, we did observe a substantial increase of RhoA expression ( Figure 3C ). Figure 3D shows the cumulative densitometric data from 4 unrelated experiments.
Finally, we set out to test whether the proPLT reduction mediated by PKCe inhibition was due to inappropriately high RhoA expression and activity. Therefore we analyzed the proPLT formation from PKCe knock-down and control samples in the presence or absence of a pharmacological RhoA inhibitor ( Figure 4A ). As shown in Figure 4B , using a well-established flow cytometric method, 19, 28 we also counted the absolute number of platelets in the culture medium. Flow cytometric analysis of functional platelets-positive for surface expression of CD41 and Calcein AM-showed that pharmacological inhibition of RhoA dramatically increased PLT formation and release in both control and PKCe-depleted samples ( Figure 4B ; a2 vs b2, c2 vs d2, and e2 vs f2; Figure 4C ). Additionally, RhoA inhibition restored normal proPLT morphology in cells depleted of PKCe expression ( Figure 4D-F) . Figure 4F shows the size distribution within the platelet populations. Ninety-five percent of the shRNACT PLTs had a diameter smaller than 3.8 mm, whereas only 42% of the shRNA59 and 35% of the shRNA60 showed a diameter comparable to that of the control. Instead, in the presence of the RhoA inhibitor, 80% of shRNA59 and 75% of shRNA60 PLT populations returned to a size similar to that of the control.
Collectively, these data show that PKCe downregulates RhoA activity to promote proPLT formation and platelet release.
Discussion
The process of platelet formation from megakaryocytes is characterized by distinct morphological stages that require extensive cytoplasmic remodeling. We had previously demonstrated that PKCe levels are specifically modulated by TPO in order to drive human hematopoietic cell precursors to PLT-producing MK. 18, 31 We now show here that PKCe expression, which is virtually absent in mouse FLC, progressively increases in TPO-treated cells, and its levels remain high also in ppfMK and isolated proPLT. In proPLT, PKCe colocalizes with a/b-tubulin, which forms the marginal tubular coil, suggesting a functional correlation with the cytoskeleton reorganization events that accompany MK diffentiation and proplatelet formation. In support of this hypothesis, we observed that downregulation of PKCe expression by specific siRNAs resulted in lower proplatelet numbers and larger diameter platelets in culture. Because the efficiency of siRNA transfection is not homogeneous, we used recombinant lentiviral vectors that coexpress PKCe-targeting shRNAs and a puromycin-resistant cassette, thus allowing for the enrichment of PKCe-depleted cells. As expected, we detected a strong numerical reduction of proPLT formation with the remaining proPLTs lacking the typical organization in connected discoid structures.
It is well known that PKCe has a key role in neurite outgrowth, 23 a process that shares aspects with proPLT formation, such as the involvement of the RhoA pathway 23 which in turn is regulated by the complex PKCe/14-3-3zeta during MK polyploidization. 22 For this reason, we subsequently asked whether PKCe regulates proPLT formation and PLT release via inhibition of RhoA.
Indeed, we found that the active form of RhoA was downregulated at the terminal phases of MK differentiation, just before proPLT production, whereas PKCe and 14-3-3zeta expression did not change. PKCe knockdown by specific shRNA resulted in a significant increase of the active RhoA expression, along with hampered proPLT formation and PLT production. Accordingly, PKCe-depleted precursors treated with the pharmacological RhoA inhibitor generated normally shaped proPLT, with long cytoplasmic extensions characterized by a network of discoid structures, and restored PLT generation both in terms of number and size. Pleines et al 14 have previously described the effects of RhoA knockdown on PLT size, showing that RhoA 2/2 mice are macrothrombocytopenic with high ploidy MKs. Given the role of RhoA in a plethora of signaling pathways, the RhoA 2/2 mouse might well be considered as a good indicator of the relevance of RhoA in megakaryopoiesis, but probably is not ideal for assessing the impact of compensatory mechanisms that represent unpredictable variables in a highly specific setting as proPLT formation. Our data show that inhibiting RhoA specifically at day 4 (preterminal phase) of proPLT formation carefully avoids perturbations of the earlier phases of cell commitment and differentiation. These data show for the first time that PKCe has a key role in mouse PLT formation, by modulation of RhoA activity and interaction with the marginal tubular coil. These results represent a valid model for unraveling the molecular regulation of PLT generation. In fact, though PKCe is not expressed in late human Densitometric measurements, performed using ImageJ software, of western blots from 3 replicates. Data are normalized for FLC (means 6 1 SD; *P , .05; **P , .01; ANOVA and Tukey tests). (C) Western blot detection of PKCe, 14-3-3zeta, and RhoA in mouse MK. At day 3 of culture, rMK untreated (un) or infected with PKCe-specific shRNA (shRNA59, shRNA60) and controls (shRNACT) were collected. GAPDH was monitored for protein loading. In the presence of PKCe-specific shRNA, the 14-3-3zeta protein levels remained stable at the control levels, whereas active RhoA expression levels sensibly increased. (D) Densitometric analysis of PKCe, 14-3-3zeta, and RhoA protein expression. Densitometric measurements, performed using ImageJ software, of western blots from 5 replicates. Data are normalized for shRNACT (means 6 1 SD; **P , .01 ANOVA and Tukey tests).
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